All In Biotech

Drug Trial Radar · NCT07390955

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

A Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and in Vitro Neutralization of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS Administered in Multiple Doses and Routes to Adult Participants Without HIV-1

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

83

Planned (sponsor's estimate)

Start

Mar 19, 2026

Primary completion

Aug 30, 2027

Study completion Aug 30, 2027

Sponsor

Sponsor type
NIH
Collaborators
National Institutes of Health (NIH); Department of Health and Human Services
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will assess safety and side effects, determine the right dose, study how the body processes the drug (pharmacokinetics or PK), and measure how well it neutralizes HIV in the blood (serum neutralizing activity). The expectation is that ePGT121v1-LS, whether given alone or with PGDM1400LS and VRC07-523LS, by IV or SC, will be safe in generally healthy adults and that the antibodies will not interfere with each other when used together. Approximately 83 volunteers in overall good health and without HIV-1 will be enrolled into two parts (A and B). Part A has six groups. In Groups 1-3, participants will get ePGT121v1-LS given by IV at one of three dose levels: 5 mg/kg, 20 mg/kg, or 40 mg/kg. In Groups 4-6, participants will receive three antibodies-first ePGT121v1-LS, then PGDM1400LS and VRC07-523LS-given by IV at two separate visits that are 24 weeks apart. The total study duration for participants in Part A is 48 weeks of scheduled clinic visits. Part B has two groups. In Group 7, people will get ePGT121v1-LS as SC shots at two visits 12 weeks apart. Each visit will give a total of 375 mg, split into three injections of 125 mg each. In Group 8, people will also have two visits 12 weeks apart and will receive three antibodies as SC shots in this order: first ePGT121v1-LS (125 mg), then PGDM1400LS (100 mg), and then VRC07-523LS (100 mg). The total study duration for participants in Part B is 24 weeks of scheduled clinic visits.

Conditions

  • HIV

Interventions

  • ePGT121v1-LS (IV)Biological

    Intravenous infusion (IV)

  • PGDM1400LS (IV)Biological

    IV infusion

  • VRC07-523LS (IV)Biological

    IV infusion

  • ePGT121v1-LS (SC)Biological

    Subcutaneous (SC) injection

  • PGDM1400LS (SC)Biological

    SC injection

  • VRC07-523LS (SC)Biological

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of participants with solicited local Adverse Events (AEs)Time frame: Baseline through Week 48
  2. Part B: Number of participants with solicited local Adverse Events (AEs)Time frame: Baseline through Week 24
  3. Part A: Percentage of participants with solicited local Adverse Events (AEs)Time frame: Baseline through Week 48
  4. Part B: Percentage of participants with solicited local Adverse Events (AEs)Time frame: Baseline through Week 24
  5. Part A: Number of participants with solicited systemic AEsTime frame: Baseline through Week 48
  6. Part B: Number of participants with solicited systemic AEsTime frame: Baseline through Week 24
  7. Part A: Percentage of participants with solicited systemic AEsTime frame: Baseline through Week 48
  8. Part B: Percentage of participants with solicited systemic AEsTime frame: Baseline through Week 24
  9. Part A: Percentage of participants with safety laboratory abnormalities meeting grade 1 AE criteria or aboveTime frame: Baseline through Week 48
  10. Part B: Percentage of participants with safety laboratory abnormalities meeting grade 1 AE criteria or aboveTime frame: Baseline through Week 24
  11. Part A: Number of participants with unsolicited AEsTime frame: Baseline through Week 48
  12. Part B: Number of participants with unsolicited AEsTime frame: Baseline through Week 24
  13. Part A: Percentage of participants with unsolicited AEsTime frame: Baseline through Week 48
  14. Part B: Percentage of participants with unsolicited AEsTime frame: Baseline through Week 24
  15. Part A: Number of participants with Serious Adverse Events (SAEs)Time frame: Baseline through Week 48
  16. Part B: Number of participants with Serious Adverse Events (SAEs)Time frame: Baseline through Week 24
  17. Part A: Percentage of participants with Serious Adverse Events (SAEs)Time frame: Baseline through Week 48
  18. Part B: Percentage of participants with Serious Adverse Events (SAEs)Time frame: Baseline through Week 24
  19. Part A: Number of participants who discontinue study product administrationTime frame: Baseline through Week 48
  20. Part B: Number of participants who discontinue study product administrationTime frame: Baseline through Week 24
  21. Part A: Percentage of participants who discontinue study product administrationTime frame: Baseline through Week 48
  22. Part B: Percentage of participants who discontinue study product administrationTime frame: Baseline through Week 24
  23. Part A: Number of participants who terminate the study earlyTime frame: Baseline through Week 48
  24. Part B: Number of participants who terminate the study earlyTime frame: Baseline through Week 24
  25. Part A: Percentage of participants who terminate the study earlyTime frame: Baseline through Week 48
  26. Part B: Percentage of participants who terminate the study earlyTime frame: Baseline through Week 24
  27. Part A: Serum Concentration of ePGT121v1-LSTime frame: Baseline through Week 48
  28. Part B: Serum Concentration of ePGT121v1-LSTime frame: Baseline through Week 24
  29. Part A: Serum Concentration of PGDM1400LSTime frame: Baseline through Week 48
  30. Part B: Serum Concentration of PGDM1400LSTime frame: Baseline through Week 24
  31. Part A: Serum Concentration of VRC07-523LSTime frame: Baseline through Week 48
  32. Part B: Serum Concentration of VRC07-523LSTime frame: Baseline through Week 24
  33. Part A: Area Under the Concentration-Time Curve (AUC) of ePGT121v1-LSTime frame: Baseline through Week 48
  34. Part B: AUC of ePGT121v1-LSTime frame: Baseline through Week 24
  35. Part A: AUC of PGDM1400LSTime frame: Baseline through Week 48
  36. Part B: AUC of PGDM1400LSTime frame: Baseline through Week 24
  37. Part A: AUC of VRC07-523LSTime frame: Baseline through Week 48
  38. Part B: AUC of VRC07-523LSTime frame: Baseline through Week 24
  39. Part A: Maximum Observed Concentration (Cmax) of ePGT121v1-LSTime frame: Baseline through Week 48
  40. Part B: Cmax of ePGT121v1-LSTime frame: Baseline through Week 24
  41. Part A: Cmax of PGDM1400LSTime frame: Baseline through Week 48
  42. Part B: Cmax of PGDM1400LSTime frame: Baseline through Week 24
  43. Part A: Cmax of VRC07-523LSTime frame: Baseline through Week 48
  44. Part B: Cmax of VRC07-523LSTime frame: Baseline through Week 24
  45. Part A: Time to Maximum Concentration (Tmax) of ePGT121v1-LSTime frame: Baseline through Week 48
  46. Part B: Tmax of ePGT121v1-LSTime frame: Baseline through Week 24
  47. Part A: Tmax of PGDM1400LSTime frame: Baseline through Week 48
  48. Part B: Tmax of PGDM1400LSTime frame: Baseline through Week 24
  49. Part A: Tmax of VRC07-523LSTime frame: Baseline through Week 48
  50. Part B: Tmax of VRC07-523LSTime frame: Baseline through Week 24
  51. Part A: Clearance (CL) of ePGT121v1-LSTime frame: Baseline through Week 48
  52. Part B: CL of ePGT121v1-LSTime frame: Baseline through Week 24
  53. Part A: CL of PGDM1400LSTime frame: Baseline through Week 48
  54. Part B: CL of PGDM1400LSTime frame: Baseline through Week 24
  55. Part A: CL of VRC07-523LSTime frame: Baseline through Week 48
  56. Part B: CL of VRC07-523LSTime frame: Baseline through Week 24
  57. Part A: Volume of Distribution (Vd) of ePGT121v1-LSTime frame: Baseline through Week 48
  58. Part B: Vd of ePGT121v1-LSTime frame: Baseline through Week 24
  59. Part A: Vd of PGDM1400LSTime frame: Baseline through Week 48
  60. Part B: Vd of PGDM1400LSTime frame: Baseline through Week 24
  61. Part A: Vd of VRC07-523LSTime frame: Baseline through Week 48
  62. Part B: Vd of VRC07-523LSTime frame: Baseline through Week 24
  63. Part A: Terminal Elimination Rate Constant (λz) of ePGT121v1-LSTime frame: Baseline through Week 48
  64. Part B: λz of ePGT121v1-LSTime frame: Baseline through Week 24
  65. Part A: λz of PGDM1400LSTime frame: Baseline through Week 48
  66. Part B: λz of PGDM1400LSTime frame: Baseline through Week 24
  67. Part A: λz of VRC07-523LSTime frame: Baseline through Week 48
  68. Part B: λz of VRC07-523LSTime frame: Baseline through Week 24
  69. Part A: Terminal Half-life (T1/2) of ePGT121v1-LSTime frame: Baseline through Week 48
  70. Part B: T1/2 of ePGT121v1-LSTime frame: Baseline through Week 24
  71. Part A: T1/2 of PGDM1400LSTime frame: Baseline through Week 48
  72. Part B: T1/2 of PGDM1400LSTime frame: Baseline through Week 24
  73. Part A: T1/2 of VRC07-523LSTime frame: Baseline through Week 48
  74. Part B: T1/2 of VRC07-523LSTime frame: Baseline through Week 24
  75. Part A: Area Under the Magnitude-Breadth Curve (AUC-MB)Time frame: Baseline through Week 48
  76. Part B: AUC-MBTime frame: Baseline through Week 24

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Alabama CRS (Site ID: 31788)

    Birmingham, Alabama · Recruiting

  • Bridge HIV CRS (Site ID: 30305)

    San Francisco, California · Recruiting

  • The Ponce de Leon Center CRS (Site ID: 5802)

    Atlanta, Georgia · Recruiting

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS) (Site ID: 30007)

    Boston, Massachusetts · Recruiting

  • Penn Prevention CRS (Site ID: 30310)

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt Vaccine (VV) CRS (Site ID: 30352)

    Nashville, Tennessee · Recruiting

  • Houston Advancing Research Team CRS (Site ID: 31473)

    Houston, Texas · Recruiting

  • Via Libre CRS (Site ID: 31909)

    Lima Cercado, Lima region, Peru · Not yet recruiting

  • Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS (CITBM) - Unidad de Ensayos Clínicos (UNIDEC) (Site ID: 31970)

    Bellavista, Provincia Constitucional del Callao, Peru · Not yet recruiting

  • Seke South CRS (Site ID: 30294)

    Chitungwiza, Zimbabwe · Not yet recruiting

  • Spilhaus CRS (Site ID: 30314)

    Harare, Zimbabwe · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.